Skip to main content
. 2018 Feb 22;9(20):15266–15274. doi: 10.18632/oncotarget.24555

Figure 2. cfDNA mutations and disease development.

Figure 2

(A) Patient OCCC13. ddTC, dose dense weekly paclitaxel and carboplatin; BEV, bevacizumab + CPT-11 + irinotecan; PLD, doxorubicin. (B) Patient OCCC25. DC, docetaxel + carboplatin. (C) Patient OCCC14. PTX, paclitaxel; GEM, gemcitabine.